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ABST RACT
Breast cancer is a major public health problem, being the most common
cancer diagnosed in women and accounting for more than 1 in 10 new
diagnoses of cancer each year. It is the most common neoplasm of
women under the age of 40 and the second leading cause of cancer death
in this age group, with more frequent detection of pathogenic mutations
in breast cancer susceptibility genes. Women with BRCA 1 and BRCA2
mutations are about 70% more likely to develop breast cancer. The
incidence is rising in most countries and it is expected to have a growing
trend in the next 20 years, despite the current efforts to prevent the
disease. In order to improve the survival rate, it is necessary to make a
diagnosis as early as possible and to initiate the appropriate therapeutic
management as soon as possible. Therefore, in order to detect breast
formations, mammography screening is very important, breast density
being an important factor in predicting the risk of breast cancer. Thus,
the presence of high breast density represents a 4-6 times higher risk of
developing breast cancer compared to women with low breast density.
Aging and menopause are also risk factors for breast cancer. Hormone
replacement therapy for postmenopausal women has the benefit of
relieving symptoms such as hot flashes, depression or sleep disturbances,
but it increases the risk of developing breast cancer.

Introduction
Breast cancer is the most common type of cancer
worldwide. At the end of 2020, breast cancer had an
incidence of 47.8%, with a mortality rate of 13.6%.
Prostate cancer was on the second position, with an
incidence of 30.7% and a mortality rate of 7.7%. The
following places were occupied by lung, colorectal and
cervical cancer [1].
Breast cancer has become the most common cancer
globally since 2021, accounting for 12% of all new annual
cancer cases worldwide, according to the World Health
Organization. It is the most commonly diagnosed cancer in
women in the United States, in addition to skin cancers, and
about one in 8 women (about 13%) will develop invasive
breast cancer throughout their lifetime, compared to a man's
lifetime risk of breast cancer, which is about 1 in 833 [2].
By 2022, it is estimated that about 30% of the newly
diagnosed cancers in women will be breast cancer. In
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women under the age of 45, breast cancer is more common
among women of color than in white women, and
consequently the death rate is higher for this group. For
Asian, Hispanic, and Native American women, the risk of
developing and implicitly the risk of dying from breast
cancer is lower [3].
Most patients discover their disease during a routine
screening, or by accidental discovery of a lump, a change
in the shape or size of the breast or a nipple discharge. Also,
the history of cosmetic augmentation surgery may be a
source of concern about breast implant illness [3,4]. These,
along with mastalgia, are relatively common, causing
significant anxiety in the patient and leading to the
appointment to a specialist. This will include an initial
assessment and a detailed medical history along with
physical examination. Mammography is usually preferred
to support the diagnosis of breast cancer, but
ultrasonography appears to be more sensitive in women
under 30 years of age [5].
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About 5-10% of breast cancers may be related to known
and inherited genetic mutations, and breast cancer in the
history of first-degree relatives may double the risk of
developing the disease. However, fewer than 15% of
women who develop breast cancer have a family member
diagnosed with it, with the male hereditary collateral
component present in 50% of the cases [6].
Mutations in the BRCA1 and BRCA2 genes should be
diagnosed in cases where a hereditary predisposition is
suspected. On average, women with a BRCA1 mutation
have a lifetime risk of up to 72% of developing breast
cancer, and those with a BRCA2 mutation have a 69% risk,
and tend to develop more often with breast cancer. Some
women have a higher risk of breast cancer due to a higher
rate of BRCA mutations, as colorectal cancer does [7].
About 85% of breast cancers occur in women who do
not have a family history of breast cancer. In these cases,
they develop due to genetic mutations that occur as a
result of aging and life in general, rather than inherited
mutations [7,8].
The article is an analysis of several studies on the
assessment of risk factors for breast cancer. The most
common factors and their influence on patient groups were
discussed: young or menopausal women, the presence of
genetic mutations, patients undergoing hormone
replacement therapy, women with a healthy or unfavorable
lifestyle who associate or do not consume alcohol and
tobacco. The studies were accessed through several
scientific platforms, such as PubMed, Scopus, etc.

Discussion
Breast cancer is a heterogeneous disease, whose
complexity is genetically rooted and reflected in its
phenotypic characteristics [6,8].
Luminal cancers (A and B) are characterized by the
expression of estrogen receptors (ER) and/or progesterone
receptors (PgR), while tumors enriched with human
epidermal growth factor 2 (HER2) show the overexpression
of HER2 and/ or inherent gene amplification. In triplenegative breast cancer (TN), none of the above targets
are identifiable or adequately represented for therapeutic
use [7-9].
The risk of developing breast cancer in postmenopausal
women is associated with changes in circulating sex
hormone levels and the administration of hormone
replacement therapy (MHT). Such therapy is used to
relieve common menopausal symptoms such as hot
flashes, sleep disturbances, depression, and muscle or
joint pain [10,11].
The initiation of hormone therapy for menopause may
be a safe option for women under the age of 60 who have
entered menopause less than 10 years before, who have no
history of breast cancer and who are not associated with
diseases such as stroke, thromboembolic disorders, active
liver disease or coronary heart disease [12,13].

Elevated levels of endogenous estrogen are associated
with an increased risk of breast cancer (especially the
hormone-positive form of disease) for both pre- or
postmenopausal women. However, the association of
estrogen levels with the risk of breast cancer among
premenopausal women can be difficult to measure due to
changes in the menstrual cycle [14,15].
A multicenter study on 767 premenopausal women with
breast cancer and 1,699 control patients measured estradiol,
estrone, androstenedione, dehydroepiandrosterone and
testosterone and associated positive for breast cancer [13].
At the same time, hormone therapy combined with
estrogen/ progesterone in postmenopausal women with the
uterus present increases the risk of subsequent positive ER
breast cancer. In women with a history of hysterectomy,
replacement with a single estrogen has not been associated
with an increased risk of breast cancer [11,14].
A study by Ellingjord et al. analyzed hormonal risk
factors, including reproductive factors (age at first birth,
number of pregnancies, breastfeeding), as well as other
hormonal factors (the use of oral contraceptives,
intrauterine devices and menopausal hormone replacement
therapy). The latter included only the use of estrogen or the
use of combination therapy with estrogen and progestin .
The analysis showed that the body mass index, the age at
first birth, the age at menopause, the duration of use of oral
contraceptives or intrauterine devices, and the use of
hormone therapy at menopause were positively associated
with the risk of breast cancer. The age of onset of menarche
and the number of pregnancies were associated with a low
risk [16].
Compared to women who have never been pregnant,
those with more than 3 pregnancies have a risk of about
40% or less of developing luminal breast cancer. For
HER2-positive and triple-negative tumors, there were no
statistically significant associations. The heterogenicity
test comparing triple negative cancer with luminal type A
cancer was statistically significant. Older age at first birth
has been associated with an increased risk of breast cancer
in general. Mothers older than 30 years at first birth had a
slightly increased risk of developing A-like luminal tumors
and HER2-negative B-like luminal breast cancer. The
heterogenicity test comparing each subtype with A-like
luminal breast cancer was not statistically significant for
age at first birth [16].
Abubakar et al. conducted an analysis of two study
populations from Poland and the United Kingdom. The
analysis included 2,498 women with similar luminal-like
tumors, ER + and/ or PR + for which complete data on
scores based on image analysis for ER, PR, HER2 and
Ki67 could be accessed. Patients were screened at the
Eastern Cancer Registry and Information Center. The study
included women under the age of 55 diagnosed with
invasive breast cancer from 1991-1996. The data on the
relevant clinical-pathological features, including ER, PR,
89
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HER2, histological grade, tumor size, lymph node
involvement, endocrine therapy and systemic therapy were
obtained from the clinical records. Among the patients
included in this analysis, there were 316 deaths due to
breast cancer. The results showed in both populations of
the study that most tumors (82%) were of medium or low
histological grade and only 18% of high grade, and
approximately 97% of the detected tumors were classified
as stage I and II disease. Small (<2 cm) and intermediate
(2–5 cm) tumors were predominant in both studies (98%
and 97% for the Polish population, respectively). About
70% of the tumors were invasive ductal carcinomas. Only
9% of the patients had HER2 + and this did not differ on
the study population [17].
A recent meta-analysis found a positive association
between high blood pressure and the risk of breast cancer
[18,19]. This was recently confirmed by a cohort study that
reported a positive association between arterial
hypertension and breast cancer mortality, supporting it as
an independent risk factor for breast cancer [20].
Smoking has potential breast carcinogens, and it has
been recently shown to be an increased risk factor for ERpositive breast cancer [21].
Breast cancer is the most commonly diagnosed cancer
in women worldwide, and mammographic breast density
(MD) assessment is one of the strongest factors for
assessing the risk of developing this disease. Women with
high breast density have a 4-6 times higher risk of
developing breast cancer compared to women with low
breast density [22-25]. However, studies analyzing the
relationship between MD and endogenous plasma
hormones have shown insufficient results [26-30]. MD
may be an inherited trait or influenced by breast cancer risk
factors [31,32].
A study by Howell et al. reviewed several available
mammographic density data in relation with breast cancer
risk [33]. An overview of 42 studies of white breast density
(dense breast tissue appears white on mammography, while
adipose tissue is radiolucent and it appears black) visually
assessed on mammography indicated that the relative risk
of breast cancer for women with a density of 70% or more
was 4.64 times higher compared to women with less than
5% density.
In this report, the magnitude of the risk was higher
using percentage density than for other visual density
estimation methods, such as Wolffe patterns or the Breast
Imaging Reporting and Data Classification (BI-RADS),
which divides density into four categories, visually
evaluated and widely used in the US [34].
Randomized clinical trials have shown that both MHT
with estrogen alone and estrogen plus progestogen increase
MD in postmenopausal women [35-38]. The Women’s
Health Initiative (WHI) study found that postmenopausal
women who received combined estrogen plus progesterone
90

significantly increased the incidence of breast cancer over
a 5-year period compared to the placebo group. In addition,
they showed that the frequency of mammograms with
suspicious findings in the estrogen plus progesterone group
was higher than in the placebo group [39].
The presence of estrogen receptors in the structure of
benign breast formations offers the opportunity to use
tamoxifen (a selective modulator of estrogen receptors) to
treat this pathology. Some authors suggest that low doses
of the drug may be effective in treating benign proliferative
lesions with a low incidence of side effects and a potential
benefit in preventing the development of premalignant
lesions [40].
The change in MD over time is not influenced by the
typical risk factors for breast cancer. The factors most
strongly associated with MD change are age, body mass
index, pregnancy and physical activity [41-46].
A high BMI has been positively associated with
postmenopausal breast cancer [47,48]. Several studies
have reported an inverse relationship between being
overweight and the risk of developing breast cancer at
premenopause [49]. An increased body mass index is often
associated with lifestyle. Thus, the most consistent dietary
risk factor for breast cancer is alcohol, and alcohol
consumption has been associated with higher estradiol
levels and increased mammographic density in women
with breast cancer and control [50,51].
In a large prospective study that included mainly
postmenopausal women with a healthy lifestyle, the risk of
breast cancer was low, especially for ER-positive breast
tumors [52,53]. The Nurse's Health Study cohort found a
decrease in the risk of menopausal breast cancer, especially
ER-positive, among women who did not use MHT and
adopted a healthy, alcohol-free lifestyle and without any
weight gain [54].
The UK Biobank study found that a healthy lifestyle
including diet, regular physical activity, smoking cessation
and alcohol consumption mitigates the impact of genetic
factors on breast cancer [55].
An important aspect that is difficult to assess is mental
health, as it is known that depression affects the immune
status and immune deficiencies can facilitate the
appearance and progression of tumors. Many studies
suggest an influence of psychological factors on survival,
but this link could be influenced by other factors (stage,
prognosis, aggressiveness of treatment, adherence to
treatment) [56-59].
An analysis of BRCA1 and/or BRCA2 mutations
associated a later onset of breast cancer in women who had
a healthy lifestyle [60,61]. An unfavorable lifestyle can
accelerate aging, and aging increases the risk of breast
cancer.
According to the Surveillance, Epidemiology, and End
Results (SEER) database, the likelihood of a woman
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developing breast cancer in the United States between 2013
and 2015 by age range was [61]:
• 0 - 49 years - 2.1% (1 in 49 women)
• 50 - 59 years - 2.4% (1 in 42 women)
• 60 - 69 years - 3.5% (1 in 28 women)
• 70 years and over - 7.0% (1 in 14 women)
• lifetime - 12.9% (1 in 8 women)
Numerous studies have evaluated the incidence of
breast cancer in women by age and ethnicity. A study
conducted in the United States showed a higher frequency
of breast cancer among white women [61]. Many of the
racial differences are associated with the presence of risk
factors and lifestyle. A cohort study of 156,000
postmenopausal women showed that the age-related
incidence of breast cancer for white women was higher
than for other groups. The presence of risk factors for
breast cancer explained the differences for all groups
except African Americans [62].
Mutations in the BRCA1/ BRCA2 genes affect only a
small number of women, while variation in the location or
susceptibility of low-impact common single-nucleotide
polymorphisms (SNPs) may be responsible for the
increased incidence. Common places with low penetration
have recently been identified. Their polygenic inheritance
is associated with an increased risk of breast cancer
[63,64]. SNPs are common changes in the DNA code that
are thought to be non-functional variants that occur
frequently outside of functional genes. However, the
number of validated SNPs associated with the risk of breast
cancer has now exceeded 70 and it is believed that there
may be as many as hundreds that influence the risk of
breast cancer [65,66].
Research has shown that DNA methylation is
influenced by aging. Telomere length has been proposed as
a biomarker of biological age and as a risk factor for
cancer. Some studies have shown conflicting results
between the association of telomere length and the risk of
breast cancer. A healthy lifestyle can reduce the rate of
telomere shortening and delay the onset of age-related
diseases, including breast cancer [67-70].

Conclusions
This paper highlights the complexity of risk factors and
their mechanisms of action in relation to the incidence of
breast cancer. The risk factors for breast cancer are many,
the most incriminated being genetic predisposition, the
administration of hormone replacement therapy, age and
lifestyle.
High levels of endogenous estrogen increase the risk of
breast cancer (especially hormone-positive breast cancer)
in both postmenopausal and in premenopause women.
Hormone therapy for menopause can be a safe option for
women under the age of 60, with no history of breast cancer
and who have been menopausal for up to 10 years.

Combination hormone therapy at menopause for
women with intact uterus increases the risk of ER-positive
breast cancer. The level of endogenous hormones has been
associated with an increase in the mammographic density
of the breasts. Periodic mammographic screening is an
alternative to the early detection of potentially malignant
breast lesions.
High body mass index has also been positively
associated with postmenopausal breast cancer. Alcohol
intake is associated with increased mammographic density,
and smoking with increased risk of ER-positive breast cancer.
The most common cause of breast cancer among young
women is the presence of BRCA1 or BRCA2 mutations.
Patients with these mutations are about 70% more likely to
develop breast cancer. Of the total number of cases
diagnosed with breast cancer annually, only 5-10% of the
tumors are associated with the presence of genetic
mutations.
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